expect
benefit
new
technolog
includ
effici
patient
select
clinic
trial
costeffect
treatment
pathway
patient
health
servic
profit
acceler
approach
drug
develop
regulatori
author
expect
pharmaceut
biotechnolog
industri
acceler
develop
companion
diagnost
companion
therapeut
toward
goal
safer
effect
person
medicin
expect
health
servic
fund
prescrib
adopt
new
therapeut
technolog
review
discuss
import
rang
new
approach
develop
new
reprofil
medicin
treat
common
seriou
diseas
rare
diseas
new
network
pharmacolog
approach
adapt
trial
design
enrich
popul
like
respond
safe
treatment
assess
companion
diagnost
respons
toxic
risk
use
real
world
data
case
studi
describ
singl
multipl
protein
drug
target
sever
import
therapeut
area
case
studi
also
illustr
valu
complex
use
select
biomark
clinic
respons
risk
advers
drug
effect
either
singli
combin
franci
collin
director
us
nation
institut
health
state
centuri
centuri
biolog
nation
invest
biomed
research
reap
untold
reward
economi
health
peopl
collin
assert
reflect
optim
two
front
better
character
diseas
lead
effect
safer
use
current
treatment
common
longterm
medic
disord
new
biomed
technolog
expertis
acceler
develop
improv
treatment
new
treatment
none
current
exist
particular
interest
new
approach
current
refractori
cancer
resolv
acquir
resist
cancer
chemotherapi
resist
antimicrobi
chemotherapi
abil
deal
rapidli
epidem
viral
diseas
ebola
hemorrhag
fever
sar
sever
acut
respiratori
syndrom
mer
miiddl
eastern
respiratori
syndrom
develop
diseasemodifi
treatment
rare
inherit
diseas
improv
treatment
endem
infect
develop
world
current
treatment
toxic
poorli
effect
avail
person
use
medicin
need
involv
develop
right
drug
parallel
biomark
respons
diseas
outcom
advers
drug
reaction
adr
acceler
drug
develop
usual
mean
depend
surrog
marker
respons
regul
need
ensur
longterm
monitor
report
systemat
clinic
import
endpoint
coupl
right
continu
licens
medicin
clinic
use
review
consid
extent
promis
may
met
respect
precis
medicineth
applic
molecular
approach
improv
effect
safeti
use
medicin
within
stratifi
group
patient
welldefin
genotyp
phenotyp
review
also
discuss
import
time
develop
companion
diagnost
improv
treatment
plan
select
patient
increas
likelihood
effect
reduc
risk
advers
affect
associ
companion
therapeut
usa
drug
regulatori
author
food
drug
administr
describ
person
medicin
marburg
kvamm
note
mean
creation
drug
medic
devic
uniqu
patient
rather
abil
classifi
individu
subpopul
differ
suscept
particular
diseas
respons
specif
treatment
prevent
therapeut
intervent
concentr
benefit
spare
expens
side
effect
reflect
clinic
practic
deliv
person
medicin
precis
medicin
stratifi
approach
treatment
smaller
subgroup
patient
technolog
test
biomark
drug
effect
toxic
becom
increasingli
afford
around
rare
genet
diseas
includ
registri
prepar
us
nation
organ
rare
disord
nord
nord
also
provid
support
develop
rare
diseas
registri
within
ambit
european
union
registri
play
vital
role
identifi
patient
famili
will
take
part
research
new
improv
treatment
seriou
rare
diseas
howev
even
registri
pool
new
approach
need
obtain
clinic
data
safeti
effect
treatment
small
group
patient
major
challeng
develop
drug
precis
medicin
concern
achiev
adequ
sampl
size
insight
efficaci
safeti
medicin
obtain
suffici
statist
power
understand
use
medicin
smaller
subset
patient
heterogen
variant
common
diseas
often
small
number
patient
individu
rare
diseas
interest
rapidli
grow
idea
complement
result
gold
standard
formal
random
control
trial
rct
use
real
world
data
sun
et
al
effect
possibl
access
data
homogen
content
standard
use
taxonomi
within
health
system
electron
health
record
within
diseas
registri
observ
cohort
relev
health
data
set
qualiti
big
data
obtain
within
electron
health
record
need
improv
support
new
ethic
approach
patient
confidenti
ensur
far
possibl
complet
inform
ehr
addit
new
statist
approach
need
analyz
complex
real
world
data
set
end
publicpriv
partnership
support
european
union
innov
medicin
initi
current
explor
new
approach
need
within
two
major
programm
acceler
develop
appropri
patient
therapi
adapt
smart
imi
get
real
schmidt
klungel
groenwold
project
fund
eu
innov
medicin
initi
current
limit
factor
estim
shortfal
data
analyst
need
across
eu
alon
effect
develop
mainten
analysi
current
envisag
larg
clinic
dataset
unit
state
food
drug
administr
amend
act
provid
instrument
toward
clinic
databas
develop
includ
regard
inform
patient
consent
aim
provid
access
health
data
individu
use
system
support
datapartn
subcontractor
sentinel
initi
southworth
reichman
unger
harvardbas
databas
sourc
patient
data
deriv
insur
claim
report
administr
data
sentinel
initi
southworth
et
al
alreadi
begin
use
assess
world
risk
select
drug
vaccin
provid
report
issu
drug
safeti
concern
within
month
rather
year
need
rct
outcom
fda
regul
project
aris
initi
includ
question
trival
flu
vaccin
febril
seizur
increas
risk
observ
sentinel
intern
databas
also
identifi
need
new
warn
patient
inform
leaflet
live
rotaviru
vaccin
rotarix
may
caus
intussuscept
rha
et
al
angiotensin
type
receptor
olmesartan
may
caus
sprue
import
advers
effect
fda
studi
sentinel
databas
assess
link
dabigatran
bleed
risk
illustr
challeng
use
data
dabigatran
licens
oral
activ
altern
reduc
risk
embol
stroke
patient
atrial
fibril
due
nonvalvular
caus
reli
initi
rct
indic
dabigatran
better
warfarin
prevent
stroke
similar
overal
bleed
risk
connolli
et
al
follow
market
author
dabigatran
fda
receiv
expectedli
larg
number
report
seriou
bleed
episod
associ
drug
interpret
possibl
due
underreport
bleed
due
much
older
drug
warfarin
overreport
new
drug
dabigatran
possibl
reason
includ
inabl
obtain
suffici
person
data
individu
featur
adr
report
includ
detail
patient
popul
comorbid
concurr
medic
drug
dose
whether
adjust
renal
function
southworth
et
al
sentinel
databas
suggest
fact
reli
rct
bleed
risk
intracrani
gastrointestin
hemorrhag
dabigatran
similar
warfarin
southworth
et
al
howev
author
sentinel
report
note
limit
also
includ
lack
adjust
key
variabl
includ
confound
indic
treatment
freemantl
et
al
lack
valid
whether
insur
claim
code
reflect
actual
bleed
episod
southworth
et
al
analys
plan
aim
adjust
far
possibl
key
factor
barrier
patient
willing
data
made
avail
clinic
research
anticip
resolv
patient
far
possibl
deter
allow
clinic
data
use
patient
concern
includ
agre
test
regard
person
risk
subtyp
seriou
diseas
likelihood
respond
treatment
may
advers
impact
financi
posit
eg
employ
elig
mortgag
loan
obtain
insur
cover
voluntari
agreement
insur
compani
jurisdict
previous
waiv
access
knowledg
result
test
biomark
risk
seriou
diseas
implic
reduc
likelihood
optim
respons
treatment
area
may
need
statutori
protect
voluntari
agreement
prove
insuffici
protect
patient
public
impact
test
person
risk
seriou
andor
current
untreat
diseas
risk
identifi
note
genet
test
compani
report
genotyp
million
peopl
worldwid
report
consent
let
data
use
research
chen
precis
medicin
test
may
result
depriv
patient
treatment
clinic
practic
benefit
treatment
may
better
anticip
formal
clinic
trial
singer
watkin
respons
treatment
may
influenc
compensatori
effect
mani
factor
includ
treatment
affect
drugmetabol
enzym
drug
bind
effect
comorbid
lifestyl
factor
pharmacokinet
singlenucleotid
polymorph
snp
copi
number
polymorph
cnp
gene
metabol
pathway
differ
altern
signal
pathway
singer
watkin
rais
major
ethic
question
level
certainti
potenti
benefit
precis
medicin
accept
patient
treatment
option
much
less
effect
toxic
option
within
current
therapi
grow
interest
develop
stratifi
medicin
lead
increas
import
subgroup
analys
confirmatori
clinic
trial
particular
achiev
adequ
statist
power
rel
small
subgroup
patient
ogbagab
karp
wahe
wild
hutson
gerstenberg
stallard
hamborg
parson
fried
exampl
braf
protein
regul
normal
cell
growth
braf
gene
mutat
import
tumor
growth
latestag
malign
melanoma
around
patient
aggress
tumor
type
chapman
et
al
mcarthur
et
al
exampl
adapt
trial
design
braf
enzym
inhibitor
vemurafenib
assess
treat
malign
melanoma
patient
mutat
chapman
et
al
mcarthur
et
al
reduc
cost
develop
drug
mutat
occur
around
colorect
solid
cancer
yang
et
al
suggest
braf
companion
diagnost
could
use
adapt
trial
design
studi
treatment
inhibitor
braf
addit
type
cancer
new
adapt
design
clinic
trial
includ
monitor
rel
effect
treatment
subgroup
interest
option
alter
recruit
strategi
futur
patient
entri
trial
adapt
approach
need
new
analyt
method
resolut
discuss
regul
use
result
data
applic
licens
new
drug
devic
evalu
way
stallard
et
al
medicin
adapt
pathway
patient
mapp
aim
support
new
type
clinic
trial
adapt
given
patient
respons
schulthess
chlebu
bergstrm
baelen
mapp
intend
lead
acceler
limit
commerci
market
author
patient
group
benefit
new
therapeut
agent
addit
clinic
endpoint
valid
precis
medicin
diagnost
need
initi
decis
prescrib
whether
dose
modif
need
light
genet
function
inform
individu
variabl
pharmacokinet
test
need
drug
treatment
start
monitor
diseas
outcom
monitor
advers
effect
concept
combin
diagnost
singer
watkin
appli
initi
mainli
veterinari
dental
practic
term
theranosticsus
interchang
phrase
companion
diagnosticsdescrib
mandatori
safeti
efficaci
diagnost
test
use
companion
drug
prescrib
singer
watkin
us
drug
regulatori
author
fda
defin
companion
diagnost
devic
vitro
diagnost
devic
imag
tool
provid
inform
essenti
safe
effect
use
correspond
therapeut
product
fda
therapeut
companion
diagnost
defin
combin
product
fda
within
jurisdict
fda
nation
regulatori
author
crabb
marlow
bell
newland
companion
diagnost
devic
particular
therapeut
product
stipul
instruct
use
label
diagnost
devic
correspond
therapeut
product
well
label
gener
equival
biosimilar
equival
therapeut
product
fda
mean
companion
diagnost
test
must
perform
new
partner
therapeut
prescrib
understand
whether
test
improv
costeffect
need
consider
cost
perform
interpret
assay
biomark
drug
transport
drug
cost
compar
treatment
option
exist
epidemiolog
biomark
whether
heterogen
tissu
express
singer
watkin
licens
nation
regul
pharmacogenet
companion
diagnost
coincid
approv
new
drug
aim
improv
safeti
use
potenti
toxic
drug
minim
futur
treatment
cost
result
better
treatment
effect
usa
fda
alreadi
licens
sever
companion
diagnost
devic
use
correspond
therapeut
product
fda
ideal
clinic
cost
ground
effect
companion
diagnost
devic
identifi
prior
licens
treatment
fig
form
part
strategi
major
pharmaceut
compani
exampl
new
drug
develop
roch
diagnost
develop
parallel
import
ensur
effect
treatment
select
patient
protect
predict
signific
adr
also
import
effect
plan
cost
new
treatment
cost
includ
addit
mandat
test
agre
reimburs
combin
cost
test
treatment
much
difficult
genet
biomark
companion
diagnost
devic
identifi
initi
drug
licens
biolog
biopharmaceut
typic
class
therapeut
protein
synthes
biolog
process
enabl
recombin
dna
technolog
monoclon
antibodi
mca
similar
antibodi
protein
human
immun
system
use
mca
design
specif
block
biochem
specif
cellular
target
bodi
exampl
mca
therapeut
use
given
case
studi
receptor
construct
fusion
protein
usual
base
natur
occur
receptor
link
immunoglobulin
frame
receptor
provid
construct
specif
immunoglobulinstructur
confer
stabil
nucleic
acid
biolog
also
attract
potenti
new
therapeut
agent
base
abil
current
technolog
achiev
rapid
synthesi
small
interf
rna
inhibit
gene
express
exampl
publicpriv
rnai
consortium
base
broad
institut
boston
synthes
rnai
construct
evalu
potenti
therapeut
use
target
human
mous
gene
broad
noncod
microrna
may
also
provid
biolog
option
treatment
target
pichler
calin
howev
deliveri
tissu
interest
remain
major
limit
factor
biolog
class
medicin
clinic
indic
treat
wide
rang
organbas
system
diseas
high
cost
led
interest
develop
biosimilar
ramanan
grampp
licens
much
lower
cost
howev
differ
figur
econom
attract
companion
diagnost
pharmaceut
biotechnolog
compani
reproduc
permiss
davi
furstenth
desai
manufactur
qualiti
control
may
lead
risk
unexpect
seriou
advers
effect
exampl
pure
red
cell
aplasia
result
patient
antibodi
form
biosimilar
erythropoietin
epo
macdougal
et
al
antibodi
epo
neutral
biolog
activ
administ
biolog
epo
also
endogen
epo
thu
stop
red
cell
product
bone
marrow
macdougal
et
al
drug
transport
protein
involv
pharmacokinet
mani
drug
categor
accord
role
either
cellular
uptak
elimin
transport
molecul
wen
et
al
zair
eloranta
stieger
kullakublick
influx
transport
fig
compris
organ
anion
transport
protein
oatp
organ
anion
transport
oat
organ
cation
transport
oct
transport
drug
across
figur
key
influx
transport
repres
red
gray
print
version
oval
belong
slc
protein
famili
major
efflux
transport
repres
green
gray
print
version
oval
belong
abc
protein
famili
adapt
reproduc
permiss
zair
et
al
epitheli
barrier
enterocyt
hepatocyt
renal
tubul
cell
hagenbuch
stieger
zair
et
al
efflux
transport
fig
common
among
member
atpbind
cassett
abc
superfamili
respons
cellular
efflux
drug
resist
holland
zair
et
al
perturb
transportermedi
drug
uptak
dramat
influenc
drug
pharmacokinet
manifest
includ
subtherapeut
drug
concentr
drug
resist
wen
et
al
andor
advers
effect
particular
snp
cnp
sebat
et
al
may
alter
drug
transport
protein
express
function
thu
alter
drug
pharmacokinet
frank
gardner
sparreboom
megaraj
et
al
niemi
pasanen
neuvonen
thu
import
drug
design
develop
take
account
potenti
effect
candid
bioactiv
compound
variabl
drug
transport
activ
test
pharmacogenet
function
variant
drug
transport
also
provid
opportun
develop
new
companion
diagnost
thu
patient
drug
transport
profil
may
use
predict
treatment
respons
zair
et
al
well
risk
advers
effect
treatment
cancer
wide
rang
therapeut
class
instanc
increas
protein
level
seen
tumor
colon
endometrium
esophagu
lung
prostat
stomach
testi
bladder
genet
variat
contribut
vitro
cytotox
paclitaxel
ovarian
cancer
cell
svoboda
et
al
genet
variant
also
associ
increas
irinotecaninduc
treatment
respons
surviv
colorect
cancer
patient
prospect
multicent
studi
huang
et
al
regard
efflux
transport
snp
gene
express
multidrug
resist
protein
variant
relat
substrat
inhibitordepend
function
modif
vitro
studi
reduc
express
tissu
furthermor
protein
shown
potent
abil
interact
numer
clinic
import
kinas
inhibitor
includ
imatinib
gefitinib
erlotinib
confer
cancer
treatment
resist
gong
kim
ozvegylaczka
et
al
shi
et
al
sugimoto
tsukahara
ishikawa
mitsuhashi
statin
provid
illustr
case
studi
pleiotrop
effect
drug
potenti
develop
companion
diagnost
statin
wellrecogn
reduc
incid
sever
ischaem
heart
diseas
atheromat
vascular
complic
brain
circul
inhibit
key
ratelimit
enzym
cholesterol
synthesi
hmg
coa
reductas
goldstein
brown
upregul
ldl
receptor
increas
cholesterol
scaveng
et
al
howev
statin
also
import
pleiotrop
action
koh
sakuma
quon
liao
lauf
independ
lipidlow
properti
pleiotrop
action
may
contribut
cardiovascular
benefit
statin
advers
effect
exampl
direct
hauck
et
al
hermida
et
al
rajtik
et
al
thuc
et
al
zheng
hu
indirect
evid
jenkin
griev
yacoub
singer
ozawa
et
al
experiment
model
patient
suggest
benefici
effect
statin
may
includ
improv
cardiac
function
effect
independ
cholesterollow
effect
modul
rang
signal
pathway
includ
mitig
apoptosi
rajtik
et
al
howev
recent
secondari
research
suggest
part
cardiovascular
benefit
patient
statin
treatment
may
offset
increas
incid
type
diabet
mellitu
may
caus
drug
pleiotrop
effect
sattar
et
al
metaanalysi
statin
trial
particip
assign
statin
assign
control
develop
diabet
averag
year
statin
therapi
associ
increas
risk
incid
diabet
confid
interv
ci
sattar
et
al
seriou
advers
affect
limit
abil
take
longterm
statin
treatment
rhabdomyolysisinjuri
skelet
muscl
cell
lead
leak
myoglobin
circul
risk
acut
kidney
failur
snp
popul
preval
identifi
link
seriou
statininduc
myopathi
snp
found
affect
patient
initi
report
ghatak
faheem
thompson
link
et
al
find
aros
genomewid
associ
studi
gwa
subject
confirm
develop
myopathi
control
high
daili
dose
simvastatin
mg
part
trial
particip
gwa
show
singl
highli
signific
grade
associ
myopathi
snp
within
chromosom
odd
ratio
myopathi
ci
per
copi
c
allel
ci
cc
vs
tt
homozygot
region
encod
organ
aniontransport
polypeptid
regul
hepat
uptak
statin
nearli
complet
linkag
disequilibrium
snp
link
statin
metabol
associ
myopathi
replic
trial
mg
simvastatin
daili
also
show
associ
cholesterollow
effect
simvastatin
snp
region
clearli
associ
myopathi
drug
metabol
variant
accumul
higher
concentr
blood
normal
function
transport
protein
statin
affect
includ
simvastatin
pravastatin
rosuvastatin
drug
transport
less
well
advers
effect
potenti
attribut
abnorm
variant
protein
includ
antimetabolit
methotrex
buxhoferausch
et
al
activ
metabolit
cancer
chemotherapi
irinotecan
fujita
et
al
antivir
agent
lopinavir
williamson
et
al
antibiot
rifampicin
niemi
et
al
howev
data
rifampicin
suggest
transport
may
compens
alter
uptak
drug
protein
niemi
et
al
ventricular
arrhythmia
major
caus
sudden
cardiac
death
antiarrhythm
drug
flecainid
block
sodium
channel
heart
slow
conduct
cardiac
electr
impuls
investig
howev
treatment
trial
antiarrhythm
drug
flecainid
led
excess
mortal
compar
placebo
investig
new
chemic
genom
method
allow
unrecogn
pleiotrop
benefici
harm
target
medicin
identifi
target
genet
variabl
express
potenti
benefici
drug
might
made
avail
select
patient
highrisk
genotyp
phenotyp
magic
tag
exampl
technolog
new
target
discoveri
allow
immobil
bioactiv
molecul
coupl
bacteriophag
display
follow
elisa
assay
test
interact
drug
new
put
protein
target
dilli
et
al
ladwa
dilli
clark
marsh
taylor
use
method
altern
initi
translat
exemplifi
flecainid
potenti
toxic
factor
show
bind
protein
product
gene
link
sudden
cardiac
death
taylor
clark
marsh
singer
dilli
human
epiderm
growth
factor
gijsen
et
al
normal
pathway
cell
growth
divis
growth
receptor
may
time
overexpress
cancer
cell
first
companion
diagnost
herceptest
immunohistochemistri
assay
detect
gijsen
et
al
receptor
posit
breast
cancer
hurvitz
et
al
slamon
et
al
stern
et
al
trastuzumab
develop
antibodi
bind
domain
iv
extracellular
segment
receptor
lead
reduc
cell
prolifer
due
arrest
cell
phase
cell
cycl
le
pruefer
bast
mechan
includ
activ
tumor
suppressor
inhibit
least
six
major
intracellular
signal
pathway
le
et
al
trastuzumab
also
inhibit
angiogenesi
banerje
dowsett
ashworth
martin
attribut
part
reduct
express
vascular
endotheli
growth
factor
vegf
reduc
activ
kinaseakt
pathway
kou
vatish
singer
le
et
al
use
trastuzumab
treat
breast
cancer
condit
companion
diagnost
test
confirm
breast
cancer
express
egf
receptor
around
breast
cancer
patient
express
egf
receptor
thu
may
benefit
biolog
drug
test
approv
fda
roch
ingl
nice
crabb
et
al
regulatori
agenc
companion
diagnost
use
trastuzumab
companion
therapeut
agent
first
exampl
formal
regulatori
licens
companion
diagnost
cochran
collabor
publish
secondari
research
treatment
outcom
cochran
review
report
benefit
trastuzumabcontain
therapi
metastat
breast
cancer
balduzzi
et
al
hazard
ratio
overal
surviv
ci
p
ci
p
progressionfre
surviv
author
conclud
contamin
control
studi
arm
allow
addit
trastuzumab
end
trial
may
led
true
effect
antibodi
underestim
balduzzi
et
al
trastuzumab
ineffect
egf
receptor
neg
cancer
may
caus
seriou
advers
effect
includ
allerg
reaction
heart
failur
rel
risk
drug
ci
p
balduzzi
et
al
egf
receptor
test
avoid
expos
patient
unnecessari
risk
without
benefit
reduc
cost
unnecessari
treatment
egf
receptor
identifi
treatment
target
cancer
trastuzumab
also
indic
treatment
egf
receptor
posit
metastat
gastric
cancer
gomezmartin
et
al
gastroesophag
junction
adenocarcinoma
gomezmartin
et
al
random
control
studi
assess
effect
ad
trastuzumab
combin
chemotherapi
advanc
posit
gastric
cancer
japan
kataoka
et
al
countri
incid
gastric
cancer
high
intern
comparison
charvat
et
al
cancer
chemotherapi
trial
evolv
evalu
mca
combin
target
treatment
multipl
cancer
pathway
simultan
aim
addit
synergist
effect
preclin
clinic
result
avail
antibodi
combin
henrick
schellen
huitema
beijnen
exampl
trastuzumab
pertuzumab
inhibitor
egf
receptor
dimer
alreadi
shown
benefici
combin
doubl
treatment
egf
receptor
receptor
treat
metastat
breast
cancer
median
progressionfre
surviv
increas
month
hazard
ratio
progress
death
ci
p
ad
pertuzumab
trastuzumab
combin
microtubul
assembl
inhibitor
paclitaxel
baselga
et
al
signific
increas
seriou
advers
effect
antibodi
combin
baselga
et
al
expect
combin
antibodi
would
less
toxic
convent
combin
chemotherapi
cancer
howev
metaanalysi
rct
patient
advanc
colorect
cancer
suggest
combin
bevacizumab
antiangiogen
antibodi
vegf
cetuximab
panitumumab
antibodi
egf
receptor
led
poorer
surviv
wors
toxic
lv
et
al
studi
need
assess
extent
differ
outcom
due
antibodi
characterist
cancer
treat
patient
factor
chronic
myeloid
leukemia
cml
first
human
cancer
link
acquir
genet
abnorm
philadelphia
transloc
quintascardama
cort
provid
opportun
develop
new
diagnost
select
drug
target
result
mutat
identifi
enzym
tyrosin
kinas
activ
result
fusion
part
breakpoint
cluster
region
bcr
gene
chromosom
abl
gene
chromosom
quintascardama
cort
fuse
bcrabl
protein
continu
activ
coupl
interleukin
beta
c
receptor
subunit
increas
cell
turnov
impair
dna
repair
quintascardama
cort
imatinib
develop
first
clinic
effect
tyrosin
kinas
receptor
inhibitor
tki
treat
patient
cml
posit
mutat
hochhau
et
al
hugh
et
al
obrien
et
al
diseas
commonli
proce
acceler
phase
blast
crisi
poor
clinic
outcom
intern
random
studi
interferon
versu
iri
trial
untreat
cml
chronic
phase
assess
benefit
random
imatinib
n
versu
interferonalpha
plu
cytarabin
n
hochhau
et
al
updat
iri
patient
receiv
imatinib
firstlin
therapi
report
diseas
progress
acceler
phase
blast
crisi
hochhau
et
al
estim
eventfre
surviv
year
estim
rate
freedom
progress
acceler
phase
blast
crisi
estim
overal
surviv
surviv
cmlrelat
death
hochhau
et
al
identifi
bcrabl
treatment
target
also
provid
diagnost
predict
treatment
respons
millot
et
al
transcript
level
earli
bcrabl
inhibitori
treatment
predict
shortterm
clinic
respons
longer
term
outcom
exampl
french
trial
imatinib
cml
treatment
children
ratio
month
start
drug
larger
spleen
higher
white
cell
count
compar
lower
ratio
millot
et
al
children
month
start
treatment
higher
rate
complet
cytogenet
molecular
respons
month
better
progressionfre
surviv
median
followup
month
rang
month
millot
et
al
howev
point
mutat
kinas
domain
bcrabl
reason
resist
develop
imatinib
mutat
alreadi
known
confer
resist
soverini
et
al
new
tki
see
therefor
develop
differ
profil
pathway
associ
resist
advers
effect
tyrosin
kinas
also
target
treat
rang
cancer
exampl
ckit
tyrosin
kinas
promot
growth
gastrointestin
stromal
tumor
gist
patient
ckit
posit
gist
also
respons
imatinib
joensuu
et
al
joensuu
et
al
inhibitor
effect
multipl
rang
receptor
tyrosin
kinas
eg
sunitinib
montemurro
et
al
nilotinib
blay
et
al
hugh
et
al
kim
et
al
shimoni
et
al
dasatanib
iriyama
et
al
shah
et
al
sorafenib
flaherti
et
al
zhu
et
al
tabl
also
clinic
avail
assess
treat
tyrosin
kinas
receptordriven
cancer
expect
use
inhibitor
action
multipl
receptor
tyrosin
kinas
jain
et
al
manley
et
al
eg
caus
direct
inhibit
cancer
growth
antiangiogenesi
may
improv
anticanc
effect
montemurro
et
al
dasatinib
iriyama
et
al
shah
et
al
bcrabl
src
famili
tyrosin
kinas
ph
cml
ph
imatinib
hochhau
et
al
joensuu
et
al
joensuu
et
al
bcrabl
ckit
pdgfr
ph
cml
ph
gist
pdgf
receptor
gene
rearrang
myelodysplast
myeloprolif
diseas
rearrang
system
mastocytosi
hypereosinophil
syndrom
chronic
eosinophil
leukemia
fusion
kinas
delet
nilotinib
blay
et
al
hugh
et
al
kim
et
al
shimoni
et
al
bcrabl
pdgfr
alpha
beta
ckit
sorafenib
flaherti
et
al
zhu
et
al
primari
kidney
cancer
advanc
renal
cell
carcinoma
advanc
primari
liver
cancer
hepatocellular
carcinoma
radioact
iodin
resist
advanc
thyroid
carcinoma
advanc
primari
renal
cell
carcinoma
advanc
primari
hepatocellular
carcinoma
advanc
thyroid
carcinoma
resist
radioact
iodin
sunitinib
montemurro
et
al
vegfr
pdgfr
ckit
renal
cell
carcinoma
imatinibresist
gist
acut
lymphoblast
leukemia
cml
chronic
myeloid
leukemia
coloni
stimul
factor
receptor
ddr
discoidin
domain
deceptor
ph
philadelphia
chromosom
posit
pdgfr
plateletderiv
growth
factor
receptor
vegfr
vascular
endotheli
growth
factor
receptor
sever
companion
diagnost
marker
may
need
combin
select
effect
treatment
cancer
seen
exampl
need
combin
kra
test
select
cancer
transmembran
egf
receptor
target
anticanc
treatment
rang
cancer
includ
breast
cancer
colorect
cancer
head
neck
cancer
bemanian
et
al
bennett
et
al
human
monoclon
antibodi
panitumumab
inhibit
growth
select
egf
receptor
tumor
bind
extracellular
domain
receptor
prevent
pathway
activ
bennett
et
al
howev
kra
protein
product
protooncogen
kra
gtpase
activ
help
initi
egf
receptor
cell
signal
mutat
kra
make
constitut
activ
mani
cancer
patient
constitut
activ
variant
gtpase
encod
kra
fail
respond
panitumumab
amado
et
al
peeter
et
al
kra
companion
diagnost
approv
fda
licens
panitumumab
predict
respons
antibodi
patient
egf
receptor
refractori
progress
metastat
colorect
cancer
mack
regul
limit
approv
panitumumab
use
patient
metastat
colorect
cancer
express
egf
receptor
confirm
use
companion
kra
diagnost
nonmut
suppress
kra
mack
kra
test
also
use
predict
respons
egf
receptor
antagonist
cetuximab
chimer
mousehuman
monoclon
antibodi
use
treat
patient
metastat
colorect
cancer
head
neck
cancer
krasactiv
mutat
patient
metastat
colon
cancer
studi
van
cutsem
et
al
elig
ad
cetuximab
treatment
prolong
overal
surviv
month
hazard
ratio
studi
braf
mutat
strong
indic
advers
prognosi
van
cutsem
et
al
contrast
treatment
respons
local
advanc
metastat
nonsmal
cell
lung
cancer
gefitinib
small
molecul
select
inhibitor
egf
receptor
tyrosin
kinas
egf
receptor
activ
mutat
egf
receptor
need
present
carotenuto
et
al
hirsch
et
al
key
advanc
precis
approach
treat
brain
diseas
come
insight
immunolog
basi
wide
rang
neuropsychiatr
disord
baumeist
russel
pariant
mondelli
acut
psychosi
depress
horowitz
zunszain
dementia
possibl
associ
alter
immun
schizophrenia
suggest
centuri
ago
support
epidemiolog
genet
studi
link
infect
inflamm
schizophrenia
khandak
et
al
evid
acquir
past
decad
led
develop
new
immunolog
biomark
implic
antiinflammatori
treatment
may
diseas
andor
symptom
modifi
psychiatr
diseasesfrom
syndrom
wellphenotyp
diseas
subtyp
rais
inflammatori
marker
typic
mani
set
associ
psychosi
includ
psycholog
stress
puerper
period
bergink
et
al
infect
syndrom
sever
inflammatori
marker
may
rais
first
psychosi
tumor
necrosi
factoralpha
tnfalpha
report
di
nicola
et
al
threefold
higher
adult
patient
first
psychosi
versu
control
exampl
creactiv
protein
crp
report
rais
patient
first
psychosi
even
higher
patient
first
psychosi
also
histori
psycholog
trauma
childhood
di
nicola
et
al
hepgul
et
al
metaanalysi
result
associ
childhood
stress
inflamm
adult
first
psychosi
baumeist
et
al
identifi
studi
individu
inflammatori
marker
crp
studi
individu
studi
individu
tnfalpha
baumeist
akhtar
ciufolini
pariant
mondelli
three
inflammatori
marker
rais
adult
first
psychosi
independ
age
gender
bodi
mass
index
baumeist
et
al
observ
rais
question
whether
antiinflammatori
treatment
would
help
complement
classic
pharmacolog
treatment
psychiatri
evid
doubleblind
random
placebocontrol
trial
inhibitor
celecoxib
subject
suggest
effect
adjuv
therapi
manic
episod
bipolar
mood
disord
without
psychot
featur
patient
rais
cortisol
inflammatori
marker
poorer
respons
treatment
first
psychosi
raison
et
al
conduct
doubleblind
placebocontrol
rct
three
infus
tnfalpha
antagonist
infliximab
outpati
major
depress
either
stabl
antidepress
regimen
n
medic
free
n
week
moder
resist
treatment
raison
et
al
infliximab
infus
mgkg
baselin
week
studi
overal
effect
treatment
depress
score
howev
baselin
concentr
tnf
solubl
receptor
significantli
higher
infliximabtr
clinic
respond
versu
nonrespond
furthermor
patient
highest
level
highsensit
creactiv
protein
hscrp
like
respons
antitnfalpha
treatment
raison
et
al
significantli
greater
decreas
hscrp
baselin
week
versu
placebotr
respond
common
form
dementia
degen
typic
affect
elderli
tend
insidi
onset
slowli
progress
littl
way
neurolog
featur
brain
mri
scan
becom
atroph
two
major
degen
dementia
commonli
either
caus
alzheim
diseas
character
cerebr
plaqu
betaamyloid
neurofibrillari
tangl
atheromat
vascular
diseas
similar
cardiovascular
risk
factor
treatment
coronari
arteri
peripher
vascular
diseas
ie
manag
hypercholesterolemia
hypertens
smoke
diabet
mellitu
chronic
kidney
diseas
autoimmun
dementia
increasingli
recogn
amen
antiinflammatori
treatment
good
outcom
intens
immunosuppress
antiinflammatori
treatment
start
earli
present
pioneer
paper
vincent
colleagu
report
associ
antibodi
potassium
channel
limbic
enceph
vincent
et
al
recogn
potenti
immunotherapyrespons
form
enceph
clue
diagnosi
recogn
includ
onset
younger
middl
age
subacut
onset
presenc
confus
delirium
rapid
progress
eg
acceler
forget
hour
day
week
overt
neurolog
featur
focal
signal
chang
brain
magnet
reson
imag
support
initi
serial
immunolog
test
histor
brain
biopsi
commonli
perform
obtain
patholog
confirm
diagnosi
biopsi
larg
supersed
improv
brain
imag
algorithmsupport
guidanc
schott
et
al
diagnost
option
suspicion
autoimmun
etiolog
usual
base
detect
spectrum
antibodi
camdessanch
et
al
carvajalgonzalez
et
al
fda
hart
maddison
newsomdavi
vincent
mill
vincent
et
al
wright
et
al
complement
observ
recoveri
gener
antiinflammatori
treatment
specif
biolog
treatment
target
select
inflammatori
cytokin
patient
untreat
dens
amnesia
may
occur
associ
sever
brain
injuri
includ
major
atrophi
hippocampu
neurodegener
typic
clinic
syndrom
seen
elderli
patient
becom
transient
sever
confus
associ
episod
infect
urinari
tract
chest
earlier
hypothes
mechan
includ
disorient
infect
treat
hospit
set
away
familiar
home
environ
toxic
effect
brain
neuron
system
inflammatori
cytokin
gener
respons
infect
direct
effect
bacteremia
brain
cell
new
concept
prime
microgli
endotheli
cell
brain
minor
subclin
inflammatori
insult
may
lead
cell
becom
hyperrespons
inflammatori
stimuli
subsequ
infect
microgli
cell
toxic
effect
neighbor
brain
neuron
caus
confus
experiment
studi
mous
microgli
cell
activ
low
concentr
lipopolysaccharid
becam
hyperrespons
stimul
live
salmonella
typhimurium
effect
much
greater
age
control
young
mous
brain
lunnon
et
al
system
inflamm
result
alter
bloodbrain
barrier
permeabl
month
still
present
month
nagel
han
demarshal
belinka
nagel
thu
understand
pathway
microgli
prime
subsequ
respons
may
lead
new
possibl
target
rang
seriou
psychiatr
disord
atrisk
patient
prophylaxi
microgli
activ
event
infect
may
reduc
incid
sever
infectionassoci
confus
current
work
focus
address
microgli
mechan
respons
recent
safeti
studi
suggest
antitnfalpha
antibodi
etanercept
may
protect
confus
butchart
et
al
larger
random
control
treatment
trial
power
look
efficaci
endpoint
current
plan
cystic
fibrosi
inherit
autosom
recess
condit
clinic
diseas
occur
lossoffunct
mutat
copi
gene
cystic
fibrosi
transmembran
conduct
regul
cftr
protein
affect
homozyg
patient
thicker
secret
lung
lead
recurr
chest
infect
respiratori
failur
thick
secret
pancrea
may
also
lead
malabsorpt
due
failur
digest
enzym
enter
lumen
small
intestin
publicpriv
partnership
led
discoveri
modul
select
abnorm
cftr
protein
multipl
molecular
defect
associ
differ
mutat
cftr
protein
collawn
fu
bartoszewski
matalon
cftr
mutat
caus
diseas
limit
much
cftr
protein
reach
surfac
bronchial
epitheli
cell
wainwright
et
al
lumacaftor
increas
traffick
cftr
cell
surfac
ivacaftor
enhanc
chlorid
transport
cftr
cell
surfac
wainwright
et
al
combin
drug
result
modest
improv
lung
function
reduct
number
respiratori
infect
wainwright
et
al
test
mandatori
recommend
consider
within
individu
variabl
drugmetabol
enzym
includ
thiopurin
methyl
transferas
test
mcleod
siva
thiopurin
drug
azathioprin
minim
risk
seriou
bone
marrow
suppress
reduc
risk
irinotecaninduc
diarrhea
mcleod
siva
test
risk
resist
antiplatelet
prodrug
clopidogrel
mega
et
al
vitamin
k
epoxyreductas
test
anticoagul
respons
warfarin
averi
et
al
maitlandvan
der
zee
et
al
marker
poor
metabol
activ
risk
resist
tamoxifen
welzen
et
al
blunt
pain
relief
prodrug
codein
crew
et
al
test
udpglucoronosyltransferas
ugt
gene
variat
illustr
avoid
import
prevent
advers
effect
anticanc
drug
irinotecan
prevent
dna
uncoil
inhibit
enzym
topoisomeras
reduc
cell
growth
select
colorect
lung
cancer
l
evesqu
et
al
main
doselimit
toxic
irinotecan
treatment
diarrhea
secondari
enter
injuri
follow
biliari
excret
l
evesqu
et
al
activ
metabolit
irinotecan
glucoronid
hepat
ugt
low
activ
increas
risk
seriou
diarrhea
l
evesqu
et
al
patient
homozyg
also
greater
risk
neutropoenia
irinotecan
one
two
copi
wildtyp
allel
l
evesqu
et
al
histocompat
antigen
hla
companion
diagnost
use
reduc
risk
seriou
druginduc
skin
adr
stevensjohnson
syndrom
toxic
epiderm
necrolysi
seriou
skin
hypersensit
reaction
stevensjohnson
syndrom
due
antiretrovir
agent
abacavir
shown
associ
gene
hlab
pavlo
mallal
phillip
prospect
screen
significantli
reduc
incid
clinic
suspect
hypersensit
pavlo
et
al
approv
clinic
use
abacavir
coupl
lower
risk
result
hlab
diagnost
test
pavlo
et
al
carbamazepin
use
treat
epilepsi
neuropath
pain
bipolar
disord
acut
manic
mix
episod
associ
bipolar
disord
stevensjohnson
syndrom
toxic
epiderm
necrolysi
associ
presenc
hlab
allel
fda
advic
patient
ancestri
area
hlab
present
screen
hlab
allel
start
treatment
carbamazepin
patient
popul
greatest
risk
asia
includ
south
asia
innov
approach
need
make
hla
test
avail
cost
effect
nation
scale
increasingli
recogn
drug
clinic
use
may
sever
potenti
benefici
advers
effect
find
pleiotrop
benefit
risk
target
allow
multipl
indic
new
drug
opportun
reprofil
use
exist
drug
safeti
profil
context
alreadi
establish
predict
potenti
advers
effect
treatment
concept
network
pharmacolog
hopkin
aris
observ
mani
drug
share
type
adrcaus
mechan
mani
drug
share
similar
therapeut
effect
janga
tzako
pujol
mosca
farr
aloy
benefici
advers
effect
may
action
known
hidden
target
may
unmask
consid
network
known
diseas
mechan
known
drug
target
fig
complement
discoveri
work
silico
use
wide
rang
omic
chemic
biolog
taylor
et
al
pharmacolog
clinic
method
watkin
marsh
taylor
singer
emerg
tool
offer
platform
identifi
explor
molecular
complex
particular
diseas
tool
help
identifi
target
new
therapeut
support
companion
diagnost
identif
new
diseas
gene
pathway
molecular
relationship
among
appar
distinct
diseas
phenotyp
biolog
signific
diseaseassoci
mutat
new
biomark
complex
diseas
thu
new
drug
target
barabasi
gulbahc
loscalzo
network
pharmacolog
approach
provid
import
potenti
tool
acceler
develop
precis
medicin
strategi
reprofil
exist
drug
help
identifi
previou
unrecogn
treatment
target
improv
benefitrisk
profil
develop
new
therapeut
agent
watkin
et
al
exampl
approach
cancer
cell
map
initi
ccmi
new
ventur
aim
systemat
detail
complex
interact
among
cancer
gene
differ
diseas
healthi
state
krogan
lippman
agard
ashworth
idek
initi
aim
creat
cancer
cell
map
differ
tumor
type
tool
target
disrupt
molecular
network
way
acceler
develop
precis
medicin
cancer
develop
target
medicin
cancer
chemotherapi
need
involv
detail
understand
molecular
network
allow
oncogenesisiniti
format
cancer
allow
cancer
cell
develop
resist
treatment
recognit
within
individu
patient
may
heterogen
within
cancer
tissu
mechan
sustain
cancer
growth
resist
endogen
tumor
immun
cancer
chemotherapi
state
union
address
riley
provid
strong
signal
health
polici
commun
success
persuad
govern
leader
funder
precis
better
health
patient
financi
health
economi
life
figur
networkcentr
view
drug
action
map
drugtarget
polypharmacolog
network
biolog
network
center
part
biolog
network
node
protein
target
drug
repres
color
drug
efficaci
toxic
understood
action
specif
node
hub
reproduc
permiss
hopkin
scienc
commun
major
new
invest
expect
support
chemist
biochemist
geneticist
data
analyst
wide
rang
health
profession
develop
publicpriv
partnership
member
includ
expert
academia
health
system
pharmaceut
smaller
biotechnolog
compani
patient
chariti
acceler
develop
implement
clinic
practic
new
precis
medicin
need
correspond
radic
chang
drug
regul
ensur
streamlin
system
process
time
way
drug
submiss
data
base
new
methodolog
focus
precis
medicin
small
subgroup
patient
riley
acknowledg
ds
hold
patent
sirna
technolog
work
financi
interest
magic
tag
chemic
genom
technolog
ds
member
healthcar
profession
work
parti
european
medicin
agenc
